Blood aging clock may reflect disease burden in cancer
In an observational study of 3,067 patients having primary tumors removed, one or two blood components accounted for PhenoAge’s link to cancer outcomes.
An observational study examined PhenoAge, a blood-based biological aging clock, in 3,067 patients undergoing surgery to remove their primary tumors. PhenoAge acceleration, which compares the clock’s age estimate with a person’s actual age, rose with tumor stage.
Depending on the cancer type, one or two of the clock’s eight blood components carried its link to cancer outcomes. Giving the components equal weight, rather than using weights developed for the general population, did not weaken that link. The findings suggest that PhenoAge may reflect disease burden rather than biological aging in cancer.
Why it matters
Interpreting aging clocks in cancer requires knowing whether they measure biological aging or disease burden. That distinction matters when using these clocks to study how aging relates to cancer outcomes.
Caveats
The observational design cannot establish what caused these links. The findings concern patients undergoing primary tumor removal, and the preprint has not been peer-reviewed.
The paper
Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer
Memorial Sloan Kettering Cancer Center
medRxiv, Oct 19, 2026, Open access, CC BY-NC-ND, Preprint, not peer-reviewed
